在前列腺癌中,ABCB1介导的多塞塔塞尔耐药性被埃拉斯逆转
Fangfang Chen1, Shiqi Wu1, Ni Kuang1
1Institution of Life Sciences, Chongqing Medical University, China.
The FEBS journal
|May 7, 2024
概括
埃拉斯通过促进细胞亡和克服耐药性来增强前列腺癌的多塞塔克塞尔治疗. 这通过抑制多药耐药性蛋白ABCB1来发生,从而减少瘤生长 in vivo.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
背景情况:
- 阴道抗性前列腺癌 (CRPC) 主要用多塞 (Doc) 治疗.
- 在CRPC治疗中,多西素耐药性是一个重要的临床挑战.
- 埃拉斯会诱导依赖铁的细胞死亡 (ferroptosis),并可能提高化疗的疗效.
研究的目的:
- 研究埃拉斯在克服前列腺癌中多塞塔克塞尔耐药性的作用和分子机制.
- 确定ERASTIN是否可以在CRPC模型中增强多塞塔克塞尔的疗效.
主要方法:
- 使用的CRPC细胞系对多塞素有抗性.
- 评估了埃拉斯和多塞塔克塞尔组合对亡和铁亡标记物的影响.
- 研究了埃拉斯对ATP结合盒子子子家族B成员1 (ABCB1) 的活性,表达和局部化的影响.
- 使用小鼠模型在体内评估瘤生长.
主要成果:
- CRPC细胞系表现出对多塞素的耐药性,具有降低调节的铁亡因子.
- 埃拉斯与多塞塔克塞尔联合使用,显示出协同作用的前进性亡效应.
- 埃拉斯显著抑制了ABCB1的活动,但没有改变其表达或局部.
- 埃拉斯治疗显著减少了瘤生长 in vivo.
结论:
- 埃拉斯增强了多塞塔塞尔诱导的亡,并逆转了前列腺癌中多塞塔塞尔耐药性.
- 埃拉斯的机制涉及抑制ABCB1活性,这是一个关键的多重药物耐药性载体.
- 埃拉斯显示治疗潜力作为辅助治疗克服多塞素耐药性在CRPC.
更多相关视频
相关概念视频
01:15Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K